NASDAQ:ENGN enGene (ENGN) Stock Price, News & Analysis $7.68 +0.01 (+0.13%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About enGene Stock (NASDAQ:ENGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get enGene alerts:Sign Up Key Stats Today's Range$7.54▼$7.8850-Day Range$5.50▼$9.8352-Week Range$4.42▼$18.40Volume7,668 shsAverage Volume110,289 shsMarket Capitalization$339.58 millionP/E RatioN/ADividend YieldN/APrice Target$31.43Consensus RatingBuy Company OverviewenGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Read More… The #1 ETF for monthly income (Ad)We just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could start collecting it if you act by December 19th.Click here to get the full story >> enGene Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks63rd Percentile Overall ScoreENGN MarketRank™: enGene scored higher than 63% of companies evaluated by MarketBeat, and ranked 401st out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingenGene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageenGene has only been the subject of 3 research reports in the past 90 days.Read more about enGene's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for enGene are expected to decrease in the coming year, from ($1.54) to ($1.76) per share.Price to Book Value per Share RatioenGene has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.08% of the float of enGene has been sold short.Short Interest Ratio / Days to CoverenGene has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in enGene has recently decreased by 1.93%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldenGene does not currently pay a dividend.Dividend GrowthenGene does not have a long track record of dividend growth.Read more about enGene's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.08% of the float of enGene has been sold short.Short Interest Ratio / Days to CoverenGene has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in enGene has recently decreased by 1.93%, indicating that investor sentiment is improving. News and Social Media2.6 / 5News Sentiment0.68 News SentimentenGene has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for enGene this week, compared to 24 articles on an average week.Search Interest10 people have searched for ENGN on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added enGene to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, enGene insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,651,103.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.70% of the stock of enGene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.16% of the stock of enGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about enGene's insider trading history. Receive ENGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for enGene and its competitors with MarketBeat's FREE daily newsletter. Email Address ENGN Stock News HeadlinesenGene (NASDAQ:ENGN) Earns Outperform Rating from Analysts at JMP SecuritiesNovember 21 at 5:05 AM | americanbankingnews.com'Getting the engine going': Council Bluffs kickstarting housing projectsNovember 14, 2024 | msn.comBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occidental and Chevron) pay modest dividends of 1.47% and 4%, we've found a way for regular investors to potentially earn a much bigger income stream from the energy boom.November 22, 2024 | Investors Alley (Ad)Live stream: Final rounds of 2024 engine-building competition hosted by Hendrick MotorsportsNovember 14, 2024 | msn.comUFC, IBM team up to develop enhanced fight analysis engine using watsonxNovember 14, 2024 | msn.comThese Two Mainstream Brands Have Never Built A V6 EngineNovember 14, 2024 | msn.comAnalysts Set enGene Holdings Inc. (NASDAQ:ENGN) PT at $33.67November 14, 2024 | americanbankingnews.comEncore is an AI-powered search engine for your thrifting needsNovember 11, 2024 | msn.comSee More Headlines ENGN Stock Analysis - Frequently Asked Questions How have ENGN shares performed this year? enGene's stock was trading at $9.23 at the start of the year. Since then, ENGN shares have decreased by 16.8% and is now trading at $7.68. View the best growth stocks for 2024 here. How were enGene's earnings last quarter? enGene Holdings Inc. (NASDAQ:ENGN) issued its quarterly earnings results on Tuesday, September, 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.05. Who are enGene's major shareholders? Top institutional shareholders of enGene include Point72 Asset Management L.P. (1.50%) and Wolverine Asset Management LLC (0.01%). Insiders that own company stock include De Solidarite Des Travai Fonds and Growth Opportunities F Forbion. View institutional ownership trends. How do I buy shares of enGene? Shares of ENGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of enGene own? Based on aggregate information from My MarketBeat watchlists, some other companies that enGene investors own include PayPal (PYPL), United Microelectronics (UMC), XPeng (XPEV), Adverum Biotechnologies (ADVM), AngioDynamics (ANGO), APi Group (APG) and Avino Silver & Gold Mines (ASM). Company Calendar Last Earnings9/10/2024Today11/22/2024Fiscal Year End10/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ENGN Previous SymbolNASDAQ:ENGN CUSIPN/A CIK1980845 Webwww.engene.com Phone302-273-0765FaxN/AEmployees31Year FoundedN/APrice Target and Rating Average Stock Price Target$31.43 High Stock Price Target$40.00 Low Stock Price Target$18.00 Potential Upside/Downside+299.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-99,920,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-66.38% Return on Assets-56.00% Debt Debt-to-Equity Ratio0.09 Current Ratio19.52 Quick Ratio19.52 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$4.74 per share Price / Cash Flow1.66 Book Value$3.12 per share Price / Book2.52Miscellaneous Outstanding Shares44,220,000Free Float38,158,000Market Cap$348.01 million OptionableN/A Beta-0.76 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (NASDAQ:ENGN) was last updated on 11/22/2024 by MarketBeat.com Staff From Our PartnersBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | SponsoredA “Thank You Gift” From Pres. Trump - GeniusThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredTrump Returns...Inflation Fears SkyrocketTrump's back in the White House, but here's what they're not telling you: his plans could cause inflation to s...Oasis Gold | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredThe #1 Bitcoin ETF For Monthly DividendsYou don't have to own any Bitcoin to collect BIG dividends from it... Now, thanks to this brand new Bitcoin...Investors Alley | Sponsored“Trump Trades” You’ve Got to MakeThese Stocks are the Best “Trump Trades” Free e-book reveals sectors – and stocks within them – likely to p...StockEarnings | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enGene Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share enGene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.